{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=32&q=advanced+melanoma",
    "query": {
      "q": "advanced melanoma",
      "condition": "Melanoma",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 832,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=33&q=advanced+melanoma&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=31&q=advanced+melanoma&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T13:36:49.843Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01028222",
      "title": "A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "DTIC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2010-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2015-12-30",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 14,
      "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01028222"
    },
    {
      "nct_id": "NCT00516802",
      "title": "A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma Neoplasms"
      ],
      "interventions": [
        {
          "name": "KU-0059436 (AZD2281)(PARP inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2007-01",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-05-15",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516802"
    },
    {
      "nct_id": "NCT02012231",
      "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Thyroid Cancer",
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Cholangiocarcinoma",
        "Histiocytosis",
        "Hairy Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "PLX8394",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fore Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2014-02",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02012231"
    },
    {
      "nct_id": "NCT04971499",
      "title": "A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Dapansutrile",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "April Salama, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2022-09-06",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04971499"
    },
    {
      "nct_id": "NCT04254107",
      "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Gastric Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Classical Hodgkin Lymphoma",
        "Diffuse Large B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Cutaneous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "SEA-TGT",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "DRUG"
        },
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2020-05-29",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04254107"
    },
    {
      "nct_id": "NCT02498665",
      "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Glioblastoma Multiforme",
        "Melanoma",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Sarcoma",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "DSP-7888 Dosing Emulsion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-11",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498665"
    },
    {
      "nct_id": "NCT01763164",
      "title": "Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic or Unresectable Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "MEK162",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2013-07-12",
      "completion_date": "2019-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 77,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Altamonte Springs, Florida + 46 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Bonita Springs",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763164"
    },
    {
      "nct_id": "NCT02374255",
      "title": "Improving Goals of Care Discussion in Advanced Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Primary Stage IV Hepatobiliary",
        "Esophageal",
        "Colorectal Cancer",
        "Glioblastoma",
        "Cancer of Stomach",
        "Cancer of Pancreas",
        "Melanoma",
        "Head or Neck Cancer",
        "Stage III",
        "Stage IV",
        "Lung Cancers",
        "Pancreatic Cancers"
      ],
      "interventions": [
        {
          "name": "GoC intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2016-03-15",
      "completion_date": "2018-05-16",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • New York, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374255"
    },
    {
      "nct_id": "NCT03645928",
      "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lifileucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LN-145",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "LN-145-S1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab-relatlimab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Iovance Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2019-05-07",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03645928"
    },
    {
      "nct_id": "NCT06521567",
      "title": "A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Hodgkin Lymphoma",
        "High and Low Grade Glioma",
        "Glioblastoma Multiforme (GBM)",
        "Diffuse Intrinsic Pontine Glioma (DIPG)",
        "Ependymoma",
        "Osteosarcoma",
        "Hepatic Tumors",
        "Hepatoblastoma",
        "Hepatocellular Carcinoma (HCC)",
        "Fibrolamellar Carcinoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cobolimab",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "0 Years to 21 Years"
      },
      "enrollment_count": 83,
      "start_date": "2025-03-06",
      "completion_date": "2026-10-13",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-16T13:36:49.843Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06521567"
    }
  ]
}